Tag Archives: Mark Levick MD PhD

New Sandoz Biosimilar Shows Promising Equivalency Results

Posted on 9, March 2017 by

Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®* Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis … Read the full press release →

Posted in Germany, Healthcare, Science, Technology

Tagged , , ,